relevance of the present work beyond its acute hemodynamic setup. Nonetheless, Jazwiec and colleagues⁶ can be congratulated for their efforts in highlighting an important and emerging area of cardiac surgery.

References

1. Chang CC, Veen KM, Hahn RT, Bogers AJJC, Latib A, Oei FBS, et al. Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. *Eur Heart J*. September 11, 2019 [Epub ahead of print].
2. Wang N, Fulcher J, Abeyesuriya N, McGrady M, Wilcox I, Celermajor D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. *Eur Heart J*. 2019;40:476-84.
3. Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database. *Ann Thorac Surg*. 2013; 96:1546-52.
4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739-91.
5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *J Am Coll Cardiol*. 2017; 70:252-89.
6. Jazwiec T, Malinowski M, Ferguson H, Wodarek J, Quay N, Bush J, et al. Effect of variable annular reduction on functional tricuspid regurgitation and right ventricular dynamics in an ovine model of tachycardia-induced cardiomyopathy. *J Thorac Cardiovasc Surg*. 2021;161:e277-86.
7. Kelly BJ, Ho Luxford JM, Butler CG, Huang CC, Wilusz K, Ejiofor JJ, et al. Severity of tricuspid regurgitation is associated with long-term mortality. *J Thorac Cardiovasc Surg*. 2018;155:1032-8.
8. Eishi K, Miura T, Matsumaru I, Tanigawa K, Obase K. Spiral suspension, a novel repair technique for severe functional tricuspid regurgitation. *J Thorac Cardiovasc Surg*. 2018;156:649-52.

See Article page e277.

Commentary: Addressing tricuspid annular dilation: Cinch it down but not too tight

Eric J. Charles, MD, PhD, and
Gorav Ailawadi, MD, MBA

Eric J. Charles, MD, PhD, and Gorav Ailawadi, MD, MBA

Reaching consensus today on the optimal management of functional tricuspid regurgitation (FTR) is an unlikely endeavor. The tricuspid valve, no longer forgotten, still remains understudied, with surgical technique, patient selection, and indications still debated. Often the result of left-sided heart disease, FTR is a complex pathophysiology that occurs in the setting of varying degrees of pulmonary artery hypertension, right ventricular (RV) dysfunction, annular dilation, and leaflet tethering associated with left ventricular dysfunction.¹

CENTRAL MESSAGE

In a large-animal model, moderate (~50%) rather than aggressive annular reduction was optimal correction for functional tricuspid regurgitation while preserving right ventricular function.

From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Va.

Disclosures: Authors have nothing to disclose with regard to commercial support.

Received for publication Nov 29, 2019; revisions received Nov 29, 2019; accepted for publication Nov 30, 2019; available ahead of print Dec 14, 2019.

Address for reprints: Eric J. Charles, MD, PhD, Department of Surgery, University of Virginia, PO Box 800679, Charlottesville, VA 22908 (E-mail: ec4wx@virginia.edu).

J Thorac Cardiovasc Surg 2021;161:e288-9

0022-5223/\$36.00

Copyright © 2019 by The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2019.11.117>

Jazwiec and colleagues² should be commended for investigating the complex interaction between tricuspid annular dilation and RV dilation with varying degrees of tricuspid annular reduction. Using a large-animal ovine model of tachycardia-induced cardiomyopathy, the authors identified moderate annular reduction (~50%) as the optimal correction for FTR that improves valvular function while not compromising RV function. This study is a follow-up to their previous work in healthy sheep, where they identified

tricuspid annular reduction exceeding 50% as having a detrimental effect on RV myocardial performance.³

Guidelines for concomitant tricuspid valve (TV) repair during left-sided heart surgery are an active area of clinical investigation, with reluctance among some clinicians to perform TV interventions due to increased risk of perioperative mortality, pacemaker use, and unknown effect of correction of left-sided disease on residual tricuspid regurgitation.^{4,5} Isolated TV repair is even more infrequently performed; however, the landscape for the management of tricuspid regurgitation is rapidly changing due to percutaneous transcatheter options, such as the TriClip (off-label use of MitraClip [Abbott, Santa Clara, Calif]).⁵⁻⁷ With an increasing focus on treating the TV, it is prudent for us to further understand effective techniques for valve modulation using translational animal studies. Identifying the optimal degree of tricuspid annular reduction, and its effect on RV geometry and function, is an important aspect of the management of FTR that Jazwiec and colleagues have been addressing with their work.^{1,8,9}

The strengths of this study were the rigorous experimental protocol, the large-animal model, and the comprehensive data acquisition, including hemodynamics, echocardiographic data, and sonomicrometric data. Although the findings of this study improve our understanding of the interplay between tricuspid annular reduction and RV function, there are many important limitations. Sample size was small, and only aggressive annular reduction resulted in significantly decreased FTR. Data collection was performed in open-chested animals at 30 minutes after weaning from bypass. Since FTR is highly dependent on volume status, closing the chests and following their echocardiogram over a longer period of time are necessary next steps. In addition, the authors used a DeVega-like progressive suture annuloplasty, which is not consistent with current clinical practice.

Overall, this is an interesting study that investigates a complex problem with highly interdependent anatomy and geometry between both ventricles, septum, and TV. This study demonstrates that downsizing annuloplasty may not be effective alone for the management of FTR and sets the groundwork for future studies. With clinically relevant translational research studies such as this one, we may one day put the issue of how to best manage FTR to bed.

References

1. Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. *J Am Coll Cardiol*. 2015;65:2331-6.
2. Jazwiec T, Malinowski M, Ferguson H, Wodarek J, Quay N, Bush J, et al. Effect of variable annular reduction on functional tricuspid regurgitation and right ventricular dynamics in an ovine model of tachycardia-induced cardiomyopathy. *J Thorac Cardiovasc Surg*. 2021;161:e277-86.
3. Malinowski M, Jazwiec T, Goehler M, Bush J, Quay N, Ferguson H, et al. Impact of tricuspid annular size reduction on right ventricular function, geometry and strain. *Eur J Cardiothorac Surg*. January 29, 2019 [Epub ahead of print].
4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *J Thorac Cardiovasc Surg*. 2014;148:e1-132.
5. Algahtani F, Berzingi CO, Aljohani S, Hijazi M, Al-Hallak A, Alkhouli M. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. *J Am Heart Assoc*. 2017;6:e007597.
6. Asmarats L, Puri R, Latib A, Navia JL, Rodes-Cabau J. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. *J Am Coll Cardiol*. 2018;71:2935-56.
7. Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. *JACC Cardiovasc Interv*. 2019;12:155-65.
8. Malinowski M, Jazwiec T, Quay N, Goehler M, Rausch MK, Timek TA. The influence of tricuspid annuloplasty prostheses on ovine annular geometry and kinematics. *J Thorac Cardiovasc Surg*. 2021;161:e191-207.
9. Jazwiec T, Malinowski M, Bush J, Goehler M, Quay N, Parker J, et al. Right ventricular free wall stress after tricuspid valve annuloplasty in acute ovine right heart failure. *J Thorac Cardiovasc Surg*. 2019;158:759-68.